Biopharma | June 04, 2025
Sanofi exercises license extension option to Nurix’s STAT6 program
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
Biogen paid Ionis a US $ 60 million one-time upfront payment
The collaboration is focused on overcoming a major limitation in existing cancer drugs
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
Three-city educator training programme equips teachers with practical strategies to improve healthcare English instruction and prepare professionals for global workforce demands
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
